- Celltrion UK has inaugurated its new UK headquarters in Uxbridge, marking a key step in its strategic expansion.
- The site will serve as the company’s central hub for UK operations and underlines its long-term commitment to the biosimilars market.
Celltrion UK has officially launched its new UK headquarters at the Charter Building in Uxbridge, reinforcing its commitment to the British pharmaceutical and biotechnology sector.
The opening ceremony was attended by Celltrion CEO and Vice Chairman Hyoung-Ki Kim, Rosalind Campion, Director of the Office for Life Sciences, and Mark Samuels, Chief Executive of Medicines UK and the British Biosimilars Association.
Located in the heart of Uxbridge, a growing centre for pharmaceutical innovation, the new facility will serve as Celltrion’s main base of operations in the UK. The move aligns the company with other major industry names that have established a local presence, including Amgen, Gilead Sciences, and Daiichi Sankyo.
Speaking at the event, Hyoung-Ki Kim said, “The opening of our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK.”
Stay ahead of trends and best practices
